Clinical Trial Update: Descartes-25 in Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Descartes-25, a candidate from Cartesian Therapeutics, in relapsed/refractory multiple myeloma has a terminated Phase 1 study; no efficacy results are provided …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Descartes-25

Snippet

Sponsor: Cartesian Therapeutics | Conditions: Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Status: TERMINATED